NHS National Generic Pharmaceuticals Transition 2021_1
4 Lots. Transition and 33 % products: CESW 15 April 2021 to 30 September 2021 (5.5 months).
United Kingdom-Runcorn: Pharmaceutical products
2020/S 234-578982
Contract notice
Supplies
Directive 2014/24/EU
Section I: Contracting authority
I.1)Name and addresses
Postal address: 2nd Floor, Rutland House
Town: Runcorn
NUTS code: UK UNITED KINGDOM
Postal code: WA7 2ES
Country: United Kingdom
Contact person: David Ford
E-mail: david.ford1@nhs.net
Internet address(es):
Main address: https://www.england.nhs.uk/
Address of the buyer profile: https://www.england.nhs.uk/
I.2)Information about joint procurement
I.3)Communication
I.4)Type of the contracting authority
I.5)Main activity
Section II: Object
II.1.1)Title:
NHS National Generic Pharmaceuticals Transition 2021_1
II.1.2)Main CPV code
II.1.3)Type of contract
II.1.4)Short description:
Transition and 33 % products:
CESW 15 April 2021 to 30 September 2021 (5.5 months);
LSNE 15 April 2021 to 28 February 2022 (10.5 months);
NWLN 15 April 2021 to 30 June 2022 (14.5 months);
100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).
The total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority’s sole discretion) for up to a further 14.5 months).
II.1.5)Estimated total value
II.1.6)Information about lots
II.2.1)Title:
Transition 2021_1 — CESW region (Transition and 33 % Products)
II.2.2)Additional CPV code(s)
II.2.3)Place of performance
Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.
II.2.4)Description of the procurement:
NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority’s sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:
CESW 15 April 2021 to 30 September 2021 (5.5 months);
LSNE 15 April 2021 to 28 February 2022 (10.5 months);
NWLN 15 April 2021 to 30 June 2022 (14.5 months);
100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).
II.2.5)Award criteria
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
II.2.10)Information about variants
II.2.11)Information about options
Options to extend (at the Authority’s sole discretion) for up to a further 5.5 months.
II.2.13)Information about European Union funds
II.2.1)Title:
Transition 2021_1 — LSNE region (Transition and 33 % Products)
II.2.2)Additional CPV code(s)
II.2.3)Place of performance
Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.
II.2.4)Description of the procurement:
NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority’s sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:
CESW 15 April 2021 to 30 September 2021 (5.5 months);
LSNE 15 April 2021 to 28 February 2022 (10.5 months);
NWLN 15 April 2021 to 30 June 2022 (14.5 months);
100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).
II.2.5)Award criteria
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
II.2.10)Information about variants
II.2.11)Information about options
Options to extend (at the Authority’s sole discretion) for up to a further 10.5 months.
II.2.13)Information about European Union funds
II.2.1)Title:
Transition 2021_1 — NWLN region (Transition and 33 % Products)
II.2.2)Additional CPV code(s)
II.2.3)Place of performance
Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.
II.2.4)Description of the procurement:
NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority’s sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:
CESW 15 April 2021 to 30 September 2021 (5.5 months);
LSNE 15 April 2021 to 28 February 2022 (10.5 months);
NWLN 15 April 2021 to 30 June 2022 (14.5 months);
100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).
II.2.5)Award criteria
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
II.2.10)Information about variants
II.2.11)Information about options
Options to extend (at the Authority’s sole discretion) for up to a further 14.5 months.
II.2.13)Information about European Union funds
II.2.1)Title:
Transition 2021_1 — 100 % Products (all Regions)
II.2.2)Additional CPV code(s)
II.2.3)Place of performance
Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.
II.2.4)Description of the procurement:
NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority’s sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products:
CESW 15 April 2021 to 30 September 2021 (5.5 months);
LSNE 15 April 2021 to 28 February 2022 (10.5 months);
NWLN 15 April 2021 to 30 June 2022 (14.5 months);
100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).
II.2.5)Award criteria
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
II.2.10)Information about variants
II.2.11)Information about options
Options to extend (at the Authority’s sole discretion) for up to a further 10.5 months.
II.2.13)Information about European Union funds
Section III: Legal, economic, financial and technical information
III.1.2)Economic and financial standing
III.2.2)Contract performance conditions:
See KPI’s in procurement documents.
Section IV: Procedure
IV.1.1)Type of procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
IV.1.8)Information about the Government Procurement Agreement (GPA)
IV.2.2)Time limit for receipt of tenders or requests to participate
IV.2.4)Languages in which tenders or requests to participate may be submitted:
IV.2.6)Minimum time frame during which the tenderer must maintain the tender
IV.2.7)Conditions for opening of tenders
Runcorn.
Commercial Medicines Unit employee.
Section VI: Complementary information
VI.1)Information about recurrence
VI.2)Information about electronic workflows
VI.3)Additional information:
Responding to this notice; any supplier may be disqualified who does not respond to the following in the requisite manner.
1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at http://health.atamis.co.uk Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:
1.1) if not already registered, candidates should register on the eTendering portal at http://health.atamis.co.uk and click the link to register:
— agree to the user agreement,
— populate company details;
1.2) once registered, candidates must register interest as follows:
— log to the portal,
— select ‘Find Opportunities’ from the supplier home screen, use the ‘Sort by’,
— facility to find this opportunity and select the bold blue title to select,
— review opportunity details and click ‘Register Interest’,
— as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity),
1.3) There is a supplier user guide on using the system and candidates can contact the Atamis helpdesk at supporthealth@atamis.co.uk or by calling 08009956035 for technical assistance when completing responses.
2) General supplier information. To manage and assess supplier information the contracting authority requests candidates provide their company profile in the Government’s supplier registration service (which has replaced sid4gov), as follows:
2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.uk and select ‘Register’ at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on the system.
2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B.
2.3) For further help or information concerning this telephone +44(0) 1614137982 or via the message function on the website.
Other contracting authorities. The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.
VI.4.1)Review body
Postal address: Strand
Town: London
Postal code: WC2A 2LL
Country: United Kingdom
Internet address: https://www.gov.uk/courts-tribunals
VI.5)Date of dispatch of this notice: